^
    Back
    Association details:
    Biomarker:CD163 elevation
    Cancer:Mantle Cell Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor) +
    Rituxan (rituximab) (CD20 inhibitor) +
    lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ICML 2023
    Title:

    SOLUBLE MACROPHAGE MARKER SCD163 PREDICTS OUTCOME IN BOTH CHEMOIMMUNOTHERAPY AND TARGETED THERAPY TREATED MANTLE CELL LYMPHOMA

    Published date:
    06/09/2023
    Excerpt:
    We found that high sCD163 at diagnosis was associated with shorter progression-free survival (PFS) and shorter overall survival (OS) (log rank test p = 0.002 and p < 0.001, respectively) in 81 newly diagnosed patients that were subsequently treated with chemoimmunotherapy. The same was seen in a cohort of 50 relapsed, heavily pretreated, MCL patients mainly treated within the phase II Philemon-trial with rituximab, ibrutinib and lenalidomide (log rank test, PFS p = 0.016 and OS p = 0.035).
    DOI:
    https://doi.org/10.1002/hon.3165_597
    Trial ID:
    PHILEMON